Fig. 3: KDM5B promotes the progression and cisplatin resistance of NPC by directly inhibiting the expression of ZBTB16. | Cell Death & Differentiation

Fig. 3: KDM5B promotes the progression and cisplatin resistance of NPC by directly inhibiting the expression of ZBTB16.

From: Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16/TOP2A axis

Fig. 3

a, b HNE1 and CNE2 cells were infected with shControl or shZBTB16 for 48 h. Then, cells were transfected with pcDNA3.1 or myc-KDM5B as indicated. After 24 h, cells were harvested for Western blotting analysis (a) and RT-qPCR analysis (b). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. Data presented as Mean ± SD with three replicates. NS not significant; *P < 0.05; ***P < 0.001. cg HNE1 and CNE2 cells were infected with indicated shRNAs for 72 h. Cells were collected for Western blotting analysis (c), RT-qPCR analysis (d), colony-formation assay (e, only HNE1 cells) and transwell assay (f, only HNE1 cells) and MTS assay (g, only HNE1 cells). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. Data presented as Mean ± SD with three replicates. NS not significant; *P < 0.05; ***P < 0.001. h HNE1 cells were infected with indicated shRNAs. After 72 h puromycin selection, cells were harvested and subcutaneously injected into nude mice for xenografts assay. Tumor volumes were measured every 3 days. Tumors were harvested, photographed, and weighed. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. Data presented as Mean ± SD with five replicates. NS not significant; **P < 0.01; ***P < 0.001. i HNE1 and CNE2 cells were infected with shControl or shZBTB16 plasmid for 48 h. then cells were treated with or without cisplatin (4 μg/ml) for another 48 h. Cells were collected for CCK-8 assay. j HNE1 and CNE2 cells were infected with indicated shRNAs for 72 h. Cells were treated with a serial dose of cisplatin. Then, these cells were collected for CCK-8 assay and subjected to measure the IC50 values of cisplatin. k HNE1 and CNE2 cells were infected with indicated shRNAs for 48 h. then cells were treated with or without cisplatin (4 μg/ml) for another 48 h. Cells were collected for colony-formation assay. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. Data presented as Mean ± SD with three replicates. *P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page